Prot#CLCI699C2X01B: An Open-label, Multi-Center, Roll-Over Study to Assess Long Term Safety in Patients with Endogenous Cushing’s Syndrome Who Have Completed a Prior Novartis-Sponsored Osilodrostat (LCI699) Study and are Judged by the Investigator to Bene